Treatment strategies for chronic lymphocytic leukemia in the era of novel targeted therapies

DOI Web Site PubMed
  • KOJIMA Kensuke
    Department of Hematology, Kochi Medical School, Kochi University

Bibliographic Information

Other Title
  • 分子標的治療時代の慢性リンパ性白血病治療戦略
  • ブンシ ヒョウテキ チリョウ ジダイ ノ マンセイ リンパセイ ハッケツビョウ チリョウ センリャク

Search this article

Abstract

<p>Molecular targeted therapies with small molecule inhibitors and antibodies have rapidly replaced chemoimmunotherapy, which has been the gold standard of care for patients with chronic lymphocytic leukemia (CLL). We discuss the current treatment strategies for CLL with special emphasis on genomic and molecular risk factors including IGHV unmutated status, 11q deletion, and 17p deletion. Ibrutinib and venetoclax are two molecular targeted agents currently available in Japan. They are highly effective, well tolerated, and have improved overall survival. Therefore, molecular targeted therapies are preferred to chemoimmunotherapy for most patients. Ongoing studies will clarify the optimal option between combination and sequence of treatment regimens with an appropriate timing of therapeutic intervention for longer survival. We are nearing an era of chemotherapy-free CLL management.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 61 (9), 1275-1280, 2020

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top